This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J Announces EU Regulatory Approval for Actelion Deal
by Zacks Equity Research
Johnson & Johnson (JNJ) has received a regulatory approval from the European Commission (EC), thus completing all necessary formalities to close the pending acquisition of Swiss biopharmaceutical company, Actelion Ltd.
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss
by Zacks Equity Research
United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017
After Johnson & Johnson Earnings, Buy These Pharma Stocks
by Ryan McQueeney
Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.
United Therapeutics Tanks, Remodulin Pump Launch Delayed
by Zacks Equity Research
United Therapeutics Corporation (UTHR) shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for delivering Remodulin
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
by Zacks Equity Research
United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.
4 Drug Stocks that are Broker Favorites
by Arpita Dutt
Here's a look at 4 drug stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies.
J&J to Acquire Actelion for $30B: Is It a Strategic Fit?
by Zacks Equity Research
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Actelion (ALIOF) for $280 per share, as of Jan 25, 2017, in an all-cash transaction.
Biotech Stock Roundup: Synergy Drug Gets FDA Nod, AbbVie, GILD HCV Drugs under EU Review
by Arpita Dutt
There were quite a few updates on the regulatory front this week in the biotech sector including FDA approval for Synergy's (SGYP) drug.
J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.
5 Best Performing Healthcare Mutual Funds of 2016
by Zacks Equity Research
Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions
J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
by Zacks Equity Research
Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.
VIVUS Licenses Rights to PAH Drugs from Selten Pharma
by Zacks Equity Research
VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
by Arpita Dutt
Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?
United Therapeutics' PAH Suite Bodes Well, Competition Rife
by Zacks Equity Research
On Dec 29, 2016, we issued an updated report on United Therapeutics Corporation (UTHR).
J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?
by Zacks Equity Research
In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).
Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
by Arpita Dutt
Biotech stocks like Conatus (CNAT) and Clovis reported positive developments this week with one company signing a deal and the other getting accelerated FDA approval for its cancer treatment.
Company News for December 15, 2016
by Zacks Equity Research
Companies In The News are: ABM,JNJ,ALIOF,HTZ,VRX
J&J (JNJ) Ends Deal Talks with Actelion: Will Sanofi Gain?
by Zacks Equity Research
On Tuesday, Johnson & Johnson (JNJ) announced that it has ended talks regarding a possible transaction with Swiss biotechnology company, Actelion Ltd. (ALIOF), reportedly for a disagreement over the purchase price.
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
by Arpita Dutt
This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.
Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno
by Arpita Dutt
With Johnson & Johnson eyeing Actelion (ALIOF), will mergers and acquisitions pick pace in the biotech sector?
Stock Market News for November 28, 2016
by Zacks Equity Research
New Strong Buy Stocks for August 17th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday